Your session is about to expire
← Back to Search
Behavioural Intervention
BIS Monitor Anesthesia for Neurocognitive Disorder (POEGEA Trial)
N/A
Recruiting
Led By Philippe Richebé, MD, PhD
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Expected anesthesia time of more than 60 minutes
Patients 70 years of age or older
Must not have
Known diagnosis of dementia or other neurological, psychiatric, developmental, or medical condition that resulted in documented severe cognitive impairment
Inability to communicate in French or English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up intraoperative
Awards & highlights
No Placebo-Only Group
Summary
This trial will study whether using EEG-guided anesthesia can reduce the incidence of postoperative neurocognitive disorders in patients aged 70 years and over, compared to using age-adjusted minimum alveolar concentration.
Who is the study for?
This trial is for patients aged 70 or older who are undergoing major non-cardiac surgery and have an expected anesthesia time over 60 minutes. They must be able to communicate in English or French, without severe cognitive impairments from conditions like dementia, and not require emergency surgery.
What is being tested?
The study tests if EEG-guided anesthesia can reduce postoperative neurocognitive disorders compared to standard care in elderly patients after major surgery. One group's anesthesia is adjusted using BIS monitor readings; the control group receives a standard dose of sevoflurane.
What are the potential side effects?
While specific side effects aren't listed, general risks may include typical reactions to anesthesia such as nausea, confusion, muscle aches, itching or chills. The focus on neurocognitive effects suggests monitoring for memory issues or altered mental state.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My surgery is expected to last over an hour under anesthesia.
Select...
I am 70 years old or older.
Select...
I had major surgery with general anesthesia recently.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a condition like dementia that severely affects my thinking.
Select...
I cannot communicate in French or English.
Select...
I need surgery urgently.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ intraoperative
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intraoperative
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Postoperative neurocognitive disorder day 1 (Yes/No); dichotomic result.
Secondary study objectives
Awareness (Yes/no); dichotomic result
Cognitive Trajectories: Evolution of T-MoCA over time (score /22 without unit)
Postoperative delirium (Yes/No); dichotomic result
+13 moreOther study objectives
Postoperative neurocognitive disorder day 1 (Yes/No); dichotomic result; among prespecified subgroups of patients
Postoperative neurocognitive disorder day 15 (Yes/No); dichotomic result; among prespecified subgroups of patients
Neurocognitive Disorders
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Electroencephalographic (EEG)-guided groupActive Control1 Intervention
Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
Group II: Standard Care (SC) groupActive Control1 Intervention
In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
Find a Location
Who is running the clinical trial?
Ciusss de L'Est de l'Île de MontréalLead Sponsor
78 Previous Clinical Trials
6,101 Total Patients Enrolled
MedtronicIndustry Sponsor
619 Previous Clinical Trials
763,774 Total Patients Enrolled
Philippe Richebé, MD, PhDPrincipal InvestigatorHôpital Maisonneuve-Rosemont - CIUSSS de l'Est de l'Ile de Montréal - Canada
3 Previous Clinical Trials
695 Total Patients Enrolled